Dexamethasone for Cerebral Toxoplasmosis

Launched by UNIVERSITAS PADJADJARAN · Apr 7, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called dexamethasone to help treat cerebral toxoplasmosis, a serious brain infection often seen in people with HIV. The goal is to see if giving dexamethasone alongside standard treatments can reduce swelling in the brain caused by the infection. This swelling can lead to severe complications, so finding the right dose and duration of dexamethasone is important.

To participate in this trial, you need to be at least 18 years old, have symptoms of cerebral toxoplasmosis, and have tested positive for HIV and for the Toxoplasma infection. Participants should not have taken dexamethasone for more than three days before joining the study. If you join, you will receive the study treatment while closely monitored by healthcare professionals. The trial is currently recruiting participants, and written consent will be required, either from you or a close relative if you are unable to give consent yourself.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18 years or above.
• • 2. Clinical signs and symptoms compatible to cerebral toxoplasmosis
• • 3. Serology HIV positive
• • 4. Immunoglobulin G anti-toxoplasma titre is positive
• • 5. One or more mass lesions on the neuroradiological finding
• • 6. None or less than 3 days of dexamethasone therapy taken
• • 7. Written informed consent from the patients or from close relatives of the patient if the patient is unconscious.
• Exclusion Criteria:
• • 1. History of anti-toxoplasmosis administrattion for more than 5 days before recruitment
• • 2. Hypersensitivity or other contraindication to dexamethasone
• • 3. Pregnancy